Treatment and management of osteoporosis-pseudoglioma syndrome

Expert Review of Endocrinology and Metabolism

Volumn 3, Issue 3, 2008, Pages 337-348

  Levasseur, Régis ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Bisphosphonates; Bone pain; LRP5; Osteoporosis; Osteoporosis pseudoglioma syndrome

Indexed keywords

BETA CATENIN; BISPHOSPHONIC ACID DERIVATIVE; C SRC KINASE INHIBITOR; CALCIUM; CATHEPSIN K INHIBITOR; CHLORIDE CHANNEL BLOCKING AGENT; CLODRONIC ACID; COLECALCIFEROL; DENOSUMAB; INTEGRIN INHIBITOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; WNT PROTEIN;

AMINO ACID SUBSTITUTION; AUTOSOMAL RECESSIVE DISORDER; BLINDNESS; BLOOD CHEMISTRY; BONE DENSITY; BONE EXAMINATION; BONE PAIN; BONE RADIOGRAPHY; BONE REMODELING; CARDIOVASCULAR SYSTEM EXAMINATION; CHILD ABUSE; CHRONIC PAIN; CLINICAL EVALUATION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SCREENING; DUAL ENERGY X RAY ABSORPTIOMETRY; EYE EXAMINATION; FRACTURE; GENE INACTIVATION; GENE MUTATION; GENETIC ANALYSIS; HEART VENTRICLE SEPTUM DEFECT; HETEROZYGOTE DETECTION; HUMAN; KINESIOTHERAPY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NONHUMAN; OCCUPATIONAL THERAPY; OPHTHALMOSCOPY; ORTHOPEDIC SURGERY; OSSIFICATION; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; OSTEOPOROSIS PSEUDOGLIOMA SYNDROME; PATHOGENESIS; PATIENT COMPLIANCE; PHYSICAL DISABILITY; PHYSIOTHERAPY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

EID: 55649086151     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/17446651.3.3.337     Document Type: Review

References (72)

1. Neuhauser G, Kaveggia EG, Opitz JM. Autosomal recessive syndrome of pseudogliomantous blindness, osteoporosis and mild mental retardation. Clin. Genet. 9(3), 324-332 (1976).
2. Saraux H, Frézal J, Roy C, Aron JJ, Hayat B, Lamy M. Pseudogliome et fragilité osseuse héréditaire à transmission autosomale recessive. Ann. Ocul. 200, 1241-1252 (1967).
3. Gong Y, Vikkula M, Boon L et al. Osteoporosis-pseudoglioma syndrome, a disorder affecting skeletal strength and vision, is assigned to chromosome region 11q12-13. Am. J. Hum. Genet. 59(1), 146-151 (1996).
4. Gong Y, Slee RB, Fukai N et al. LDL receptor-related protein 5 ( LRP5) affects bone accrual and eye development. Cell 107(4), 513-523 (2001).
5. Levasseur R, Lacombe D, de Vernejoul MC. LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders. Joint Bone Spine 72(3), 207-214 (2005).
6. Pellathy BV. Ablatio retinae und uveitis congenita bei drei Geschwistern. Z. Augenheilkd. 73, 249-254 (1931).
7. Meyer H. Atypical osteogenesis imperfecta. Lobstein's disease. Arch. Pediatr. 72, 182-186 (1955).
8. Saraux H, Miller H, Mawas J, Mawas E, Prepin F. Hyaloid-retinal dysplasia (pseudoglioma) due to recessive autosomal heredity. Ann. Ocul. 202, 1131-1137 (1969).
9. Bianchine JW, Murdoch JL. Juvenile osteoporosis (?) in a boy with bilateral enucleation of the eyes for pseudoglioma. In: Skeletal Dysplasias. Bergsma D (Ed.). National Foundation-March of Dimes, NY, USA 5, 225-226 (1969).
10. Chrysostomidou OM. Retinohyaloid dysplasia with osteoporosis and hypotonia: A syndrome with autosomal recessive transmission in a Greek family. Excerpta Medica Int. Cong. Ser. 297, 69A (1973).
11. Sauvegrain J, Dufier JL, Vacher H, Charlot JC, Ho'Ang Phuc L, Haye C. Hyaloretinal degeneration with osteoporosis and bone fragility. Pseudoglioma with bone fragility. J. Radiol. 62, 537-543 (1981).
12. Bartsocas CS, Zeis PM, Elia M, Papadatos CJ. Syndrome of osteoporosis with pseudoglioma. Ann. Genet. 25, 61-62 (1982).
13. Frontali M, Stomeo C, Dallapiccola B. Osteoporosis-pseudoglioma syndrome: Report of three affected sibs and an overview. Am. J. Med. Genet. 22(1), 35-47 (1985).
14. Beighton P, Winship I, Behari D. The ocular form of osteogenesis imperfecta: A new autosomal recessive syndrome. Clin. Genet. 28(3), 69-75 (1985).
15. Swoboda W, Grill F. The osteoporosis pseudoglioma syndrome. Update and report on two affected siblings. Pediatr. Radiol. 18(5), 399-404 (1988).
16. Teebi AS, Al-Awadi SA, Marafie MJ, Bushnaq RA, Satyanath S. Osteoporosis-pseudoglioma syndrome with congenital heart disease: A new association. J. Med. Genet. 25(1), 32-36 (1988).
17. Somer H, Palotie A, Somer M, Hoikka V, Peltonen L. Osteoporosis-pseudoglioma syndrome: Clinical, morphological, and biochemical studies. J. Med. Genet. 25(8), 543-549 (1988).
18. Spriggs DW. Case report 613: Osteoporosis pseudoglioma syndrome. Skeletal Radiol. 19(4), 302-304 (1990).
19. McDowell CL, Moore JD. Multiple fractures in a child: The osteoporosis pseudoglioma syndrome. A case report. J. Bone Joint Surg. Am. 74(8), 1247-1249 (1992).
20. De Paepe A, Leroy JG, Nuytinck L, Meire F, Capoen J. Osteoporosis-pseudoglioma syndrome. Am. J. Med Genet. 45(1), 30-37 (1993).
21. Fabian K. Osteoporosis pseudoglioma syndrome. Orv. Hetil. 136(13), 663-665 (1995).
22. Steichen-Gersdorf E, Gassner I, Unsinn K, Sperl W. Persistent hyperplastic primary vitreous in a family with osteoporosis-pseudoglioma syndrome. Clin. Dysmorphol. 6(2), 171-176 (1997).
23. Toomes C, Bottomley HM, Jackson RM et al. Mutations in LRP5 or FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q. Am. J. Hum. Genet. 74(4), 721-730 (2004).
24. Shaharao V, Shah I, Mishra P, Muranjan M, Bharucha B. Osteoporosis pseudoglioma syndrome. Indian Pediatr. 36(3), 313-315 (1999).
25. Zacharin M, Cundy T. Osteoporosis pseudoglioma syndrome: Treatment of spinal osteoporosis with intravenous bisphosphonates. J. Pediatr. 137(3), 410-415 (2000).
26. Wilson G, Moore A, Allgrove J. Bilateral retinal detachments at birth: the osteoporosis pseudoglioma syndrome. Br. J. Ophtalmol. 85(9), 1139 (2001).
27. Lee DH, Wenkert D, Whyte MP, Trese MT, Cruz OA. Congenital blindness and osteoporosis-pseudoglioma syndrome. J. AAPOS7(1), 75-77 (2003).
28. Kasten P, Bastian L, Schmid H, Coull R, Wippermann BW, Krettek C. Failure of operative treatment in a child with osteoporosis-pseudoglioma syndrome. Clin. Orthop. Relat. Res. 410, 262-266 (2003).
29. Lev D, Binson I, Foldes AJ, Watemberg N, Lerman-Sagie T. Decreased bone density in carriers and patients of an Israeli family with the osteoporosis-pseudoglioma syndrome. Isr. Med. Assoc. J. 5(6), 419-421 (2003).
30. Ai M, Heeger S, Bartels CF, Schelling DK. Clinical and molecular findings in osteoporosis-pseudoglioma syndrome. Am. J. Hum. Genet. 77(5), 741-753 (2005).
31. Levasseur R, Allanore Y, Abi Fadel M et al. A novel LRP5 mutation in the osteoporosis-pseudoglioma syndrome. Presented at: 27th Annual Meeting of the American Society for Bone and Mineral Research. PA, USA, 22-27 September 2005.
32. Lai TY, Wong VW, Lam DS. Asymmetrical ocular involvement and persistent fetal vasculature in an adult with osteoporosis-pseudoglioma syndrome. Arch. Ophthalmol. 124(3), 422-423 (2006).
33. Bayram F, Tanriverdi F, Kurtoglu S et al. Effects of 3 years of intravenous pamidronate treatment on bone markers and bone mineral density in a patient with osteoporosis-pseudoglioma syndrome (OPPG). J. Pediatr. Endocrinol. Metab. 19(3), 275-279 (2006).
34. Cheung WM, Jin LY, Smith DK et al. A family with osteoporosis pseudoglioma syndrome due to compound heterozygosity of two novel mutations in the LRP5 gene. Bone 39(3), 470-476 (2006).
35. Di Iorgi N, Maghnie M. Motor function improvement after intravenous pamidronate in osteoporosis pseudoglioma syndrome. J. Pediatr. 149(5), 734 (2006).
36. Drenser KA, Trese MT. Familial exudative vitreoretinopathy and osteoporosis-pseudoglioma syndrome caused by a mutation in the LRP5 gene. Arch. Ophthalmol. 125(3), 431-432 (2007).
37. Barros ER, Dias da Silva MR, Kunii IS, Hauache OM, Lazaretti-Castro M. A novel mutation in the LRP5 gene is associated with osteoporosis-pseudoglioma syndrome. Osteoporos. Int. 18(7), 1017-1018 (2007).
38. Lobov IB, Rao S, Carroll TJ et al. WNT7b mediates macrophage-induced programmed cell death in patterning of the vasculature. Nature 437(7057), 417-421 (2005).
39. Kellogg ND; American Academy of Pediatrics Committee on Child Abuse and Neglect. Evaluation of suspected child physical abuse. Pediatrics 119(6), 1232-1241 (2007).
40. Dubuwitz H, Bennett S. Physical abuse and neglect of children. Lancet 369(9576), 1891-1899 (2007).
41. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 363(9418), 1377-1385 (2004).
42. Newton AW, Vandeven AM. Update on child maltreatment. Curr. Opin. Pediatr. 19(2), 223-229 (2007).
43. Feldman KW, Brewer DK. Child abuse, cardiopulmonary resuscitation, and rib fractures. Pediatrics 73(3), 339-342 (1984).
44. Levasseur R, Kato M, Patel MS, Chan L, Karsenty G. Low bone mass, low body weight and abnormal eye vascularization in mice deficient in Lrp5, the gene mutated in human osteoporosis pseudoglioma syndrome (OPS). Presented at: 27th Annual Meeting of the American Society for Bone and Mineral Research. Phoenix, AZ, USA, 22-26 September 2001.
45. Hussain MM, Strickland DK, Bakillah A. The mammalian lowdensity lipoprotein receptor family. Ann. Rev. Nutr. 19, 141-172 (1999).
46. Qin M, Hayashi H, Oshima K, Tahira T, Hayashi K, Kondo H. Complexity of the genotype-phenotype correlation in familial exudative vitreoretinopathy with mutations in the LRP5 and/or FZD4 genes. Hum. Mutat. 26(2), 104-112 (2005).
47. Hartikka H, Mäkitie O, Männikkö M et al. Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children. J. Bone Miner. Res. 20(5), 783-789 (2005).
48. Mizuguchi T, Furuta I, Watanabe Y et al. LRP5, low-density-lipoprotein-receptor-related protein 5, is a determinant for bone mineral density. J. Hum. Genet. 49(2), 80-86 (2004).
49. Ferrari SL, Deutsch S, Choudhury U et al. Polymorphisms in the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with variation in vertebral bone mass, vertebral bone size, and stature in whites. Am. J. Hum. Genet. 74(5), 866-875 (2004).
50. Koller DL, Ichikawa S, Johnson ML et al. Contribution of the LRP5 gene to normal variation in peak BMD in women. J. Bone Miner. Res. 20(1), 75-80 (2005).
51. Kato M, Patel MS, Levasseur R et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J. Cell Biol. 157(2), 303-314 (2002).
52. Glass DA 2nd, Bialek P, Ahn JD et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell 8(5), 751-764 (2005).
53. Bennett CN, Longo KA, Wright WS et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc. Natl Acad. Sci. USA 102(9), 3324-3329 (2005).
54. Tamai K, Semenov M, Kato Y et al. LDL-receptor-related proteins in Wnt signal transduction. Nature 407(6803), 530-535 (2000).
55. Mao B, Wu W, Davidson G et al. Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signalling. Nature 417(6889), 664-667 (2002).
56. Li X, Zhang Y, Kang H et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt sigiialing. J. Biol. Chem. 280(20), 19883-19887 (2005).
57. Labovitz JM, Revill K. Osteoporosis: Pathogenesis, new therapies and surgical implications. Clin. Podiatr. Med. Surg. 24(2), 311-332 (2007).
58. Kasten P, Bastian L, Schmid H, Coull R, Wippermann BW, Krettek C. Failure of operative treatment in a child with osteoporosis-pseudoglioma syndrome. Clin. Orthop. Relat. Res. 410, 262-266 (2003).
59. Holick MF. Vitamin D deficiency. N. Engl. J. Med. 357(3), 266-281 (2007).
60. Straub DA. Calcium supplementation in clinical practice: A review of forms, doses, and indications. Nutr. Clin. Pract. 22(3), 286-296 (2007).
61. Bass S, Delmas PD, Pearce G, Hendrich E, Tabensky A, Seeman E. The differing tempo of growth in bone size, mass, and density in girls is region-specific. J. Clin. Invest. 104(6), 795-804 (1999).
62. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N. Engl. J. Med. 339(14), 947-952 (1998).
63. Plotkin H, Nunez M, Alvarez Filgueira ML, Zanchetta JR. Lumbar spine bone density in Argentine children. Calcif. Tissue Int. 58(3), 144-14 (1996).
64. Davie MW, Haddaway MJ. Bone mineral content and density in healthy subjects and in osteogenesis imperfecta. Arch. Dis. Child. 70(4), 331-334 (1994).
65. Reinus WR, McAlister WH, Schranck F, Chines A, Whyte MP. Differing lumbar vertebral mineralization rates in ambulatory pediatric patients with osteogenesis imperfecta. Calcif. Tissue Int. 62(1), 17-20 (1998).
66. Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 76(4), 266-283 (1997).
67. Ward L, Tricco AC, Phuong P et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst. Rev. (4), 1-36 CD005324 (2007).
68. Armingeat T, Brondino R, Pham T, Legré V. Lafforgue P. Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: A randomized double-blind controlled study. Osteoporos. Int. 17(11), 1659-1665 (2006).
69. Iwaniec UT, Wronski TJ, Liu J et al. PTH stimulates bone formation in mice deficient in Lrp5. J. Bone Miner. Res. 22(3), 394-402 (2007).
70. Grey A. Emerging pharmacologic therapies for osteoporosis. Expert Opin. Emerg. Drugs 12(3), 493-508 (2007).
71. Sabatier JP, Guaydier-Souquieres G, Benmalek A, Marcelli C. Evolution of lumbar bone mineral content during adolescence and adulthood: A longitudinal study in 395 healthy females 10-24 years of age and 206 premenopausal women. Osteoporos. Int. 9(6), 476-482 (1999).
72. Frost HM. Vital biomechanics: Proposed general concepts for skeletal adaptations to mechanical usage. Calcif. Tissue. Int. 42, 145-156 (1988).